About Prothena (NASDAQ:PRTA)
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Industry, Sector and Symbol
Trailing P/E Ratio-9.41130686870229
Forward P/E Ratio-6.51
Sales & Book Value
Annual Sales$27.52 million
Price / Sales53.39
Price / CashN/A
Book Value$10.59 per share
Price / Book3.61
Return on Equity-33.37%
Return on Assets-27.92%
Prothena (NASDAQ:PRTA) Frequently Asked Questions
What is Prothena's stock symbol?
Prothena trades on the NASDAQ under the ticker symbol "PRTA."
How were Prothena's earnings last quarter?
Prothena Co. PLC (NASDAQ:PRTA) posted its earnings results on Wednesday, February, 14th. The biotechnology company reported ($1.24) EPS for the quarter, topping analysts' consensus estimates of ($1.48) by $0.24. The biotechnology company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.27 million. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The firm's revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the business earned ($1.41) earnings per share. View Prothena's Earnings History.
When will Prothena make its next earnings announcement?
Where is Prothena's stock going? Where will Prothena's stock price be in 2018?
10 Wall Street analysts have issued twelve-month price objectives for Prothena's stock. Their predictions range from $55.00 to $100.00. On average, they anticipate Prothena's stock price to reach $75.80 in the next year. View Analyst Ratings for Prothena.
What are Wall Street analysts saying about Prothena stock?
Here are some recent quotes from research analysts about Prothena stock:
- 1. According to Zacks Investment Research, "Prothena’s narrower-than-expected loss in the fourth quarter was encouraging. The company’s efforts to develop its pipeline are encouraging as late stage candidate, NEOD001 looks promising and a potential approval will boost prospects. Moreover, Prothena's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive as it not only boosts pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates. Due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Nevertheless, shares have underperformed the industry in the last six months." (2/19/2018)
- 2. Cantor Fitzgerald analysts commented, "Friday’s announcement that the CMO will resign her position may have created some disconcerting optics, but lacking any definitive details, we caution against over-interpreting the disclosure." (2/4/2018)
Who are some of Prothena's key competitors?
Some companies that are related to Prothena include arGEN-X BV (ARGX), Ultragenyx Pharmaceutical (RARE), Crispr Therapeutics (CRSP), Horizon Pharma (HZNP), Akorn (AKRX), Supernus Pharmaceuticals (SUPN), Spark Therapeutics (ONCE), The Medicines (MDCO), Ironwood Pharmaceuticals (IRWD), Aerie Pharmaceuticals (AERI), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Myriad Genetics (MYGN), Corcept Therapeutics (CORT), USANA Health Sciences (USNA) and Esperion Therapeutics (ESPR).
Who are Prothena's key executives?
Prothena's management team includes the folowing people:
- Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board (Age 67)
- Gene G. Kinney Ph.D., President, Chief Executive Officer, Director (Age 48)
- Tran B. Nguyen, Chief Financial Officer (Age 43)
- Karin L. Walker CPA, Chief Accounting Officer, Controller (Age 53)
- Wagner M Zago, Chief Scientific Officer
- Arthur W. Homan, Chief Legal Officer (Age 57)
- Carol D. Karp, Chief Regulatory Officer (Age 64)
- Tara Nickerson Ph.D., Chief Business Officer (Age 44)
- K. Anders O. Harfstrand M.D., Ph.D., Director (Age 60)
- Richard T. Collier, Independent Director (Age 63)
Has Prothena been receiving favorable news coverage?
News coverage about PRTA stock has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prothena earned a coverage optimism score of 0.06 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Prothena's major shareholders?
Prothena's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (29.98%), BlackRock Inc. (7.72%), Alliancebernstein L.P. (2.62%), Jennison Associates LLC (1.08%), Geode Capital Management LLC (0.90%) and Pinnacle Associates Ltd. (0.88%). Company insiders that own Prothena stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena.
Which institutional investors are selling Prothena stock?
PRTA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Pinnacle Associates Ltd., Sectoral Asset Management Inc, Wells Fargo & Company MN, Bank of New York Mellon Corp, Rhumbline Advisers, TIAA CREF Investment Management LLC and Geode Capital Management LLC. Company insiders that have sold Prothena company stock in the last year include Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena.
Which institutional investors are buying Prothena stock?
PRTA stock was purchased by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Sphera Funds Management LTD., Alliancebernstein L.P., Deutsche Bank AG, First Manhattan Co., University of Notre Dame DU Lac, Renaissance Technologies LLC and Granite Point Capital Management L.P.. View Insider Buying and Selling for Prothena.
How do I buy shares of Prothena?
Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prothena's stock price today?
One share of PRTA stock can currently be purchased for approximately $38.21.
How big of a company is Prothena?
Prothena has a market capitalization of $1.30 billion and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. Prothena employs 125 workers across the globe.
How can I contact Prothena?
Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 353-1236-2500 or via email at [email protected]
MarketBeat Community Rating for Prothena (PRTA)MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Prothena (NASDAQ:PRTA) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.90||2.92||2.92||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$75.80||$76.45||$76.45||$79.33|
|Price Target Upside: ||98.38% upside||147.03% upside||111.55% upside||26.45% upside|
Prothena (NASDAQ:PRTA) Consensus Price Target History
Prothena (NASDAQ:PRTA) Analyst Ratings History
(Data available from 3/22/2016 forward)
Prothena (NASDAQ:PRTA) Earnings History and Estimates Chart
Prothena (NASDAQ PRTA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/14/2018||After Market||($1.48)||($1.24)||$0.27 million||$0.23 million||View||Listen|
|11/7/2017||Q3||($1.41)||($1.37)||$0.28 million||$0.19 million||View||N/A|
|8/8/2017||6/30/2017||($0.89)||($0.46)||$16.08 million||$26.81 million||View||N/A|
|5/9/2017||3/31/2017||($1.32)||($0.99)||$0.26 million||$0.26 million||View||N/A|
|2/14/2017||Q416||($1.12)||($1.41)||$5.35 million||$0.20 million||View||Listen|
|11/1/2016||Q3||($1.22)||($1.26)||$0.49 million||$0.29 million||View||N/A|
|8/2/2016||Q2||($0.91)||($1.18)||$0.39 million||$0.33 million||View||N/A|
|5/3/2016||Q116||($0.77)||($0.81)||$0.27 million||$0.27 million||View||N/A|
|2/18/2016||Q215||($0.81)||($0.76)||$0.39 million||$0.31 million||View||Listen|
|11/2/2015||($0.66)||($0.73)||$0.28 million||$0.43 million||View||N/A|
|8/4/2015||Q2||($0.56)||($0.59)||$0.60 million||$0.28 million||View||N/A|
|5/5/2015||($0.59)||($0.55)||$1.95 million||$0.59 million||View||N/A|
|3/5/2015||Q414||($0.66)||($0.48)||$1.20 million||$2.00 million||View||N/A|
|11/3/2014||Q314||($0.60)||($0.48)||$1.13 million||$1.50 million||View||N/A|
|8/4/2014||Q214||$0.06||$15.17 million||$15.12 million||View||N/A|
|5/5/2014||$0.81||$0.78||$30.17 million||$32.23 million||View||N/A|
|3/6/2014||Q113||($0.52)||$0.13 million||$0.17 million||View||N/A|
|11/12/2013||Q3 2013||($0.62)||($0.55)||$0.14 million||$0.17 million||View||N/A|
|8/12/2013||Q2 2013||($0.53)||($0.64)||$0.14 million||$0.17 million||View||N/A|
|5/14/2013||Q1 2013||($0.51)||$0.17 million||View||N/A|
|3/28/2013||Q412||($0.82)||$0.13 million||$0.58 million||View||N/A|
Prothena (NASDAQ:PRTA) Earnings Estimates
2018 EPS Consensus Estimate: ($5.71)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Prothena (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Prothena (NASDAQ PRTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.10%
Prothena (NASDAQ PRTA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/2/2017||Dennis J Selkoe||Director||Sell||3,500||$64.17||$224,595.00|| |
|9/28/2017||Christopher S Henney||Director||Sell||900||$70.00||$63,000.00||900|| |
|9/28/2017||Gene G Kinney||Insider||Sell||2,800||$70.00||$196,000.00||5,593|| |
|9/27/2017||Tara Nickerson||Insider||Sell||4,724||$69.05||$326,192.20||6,724|| |
|9/25/2017||Tara Nickerson||Insider||Sell||17,500||$63.60||$1,113,000.00||19,500|| |
|7/17/2017||Karin L Walker||Insider||Sell||5,000||$64.89||$324,450.00||5,000|| |
|7/7/2017||Dennis J Selkoe||Director||Sell||3,500||$58.11||$203,385.00||6,345|| |
|4/17/2017||Karin L Walker||Insider||Sell||5,000||$52.25||$261,250.00||3,000|| |
|4/3/2017||Dennis J Selkoe||Director||Sell||3,500||$55.86||$195,510.00||6,345|| |
|3/9/2017||Tran Nguyen||CFO||Buy||1,000||$51.32||$51,320.00||3,200|| |
|1/4/2017||Arthur W Homan||Insider||Sell||3,125||$52.25||$163,281.25||413|| |
|11/28/2016||Dennis J Selkoe||Director||Sell||5,000||$62.42||$312,100.00||7,845|| |
|11/9/2016||Gene G Kinney||Insider||Sell||8,548||$55.32||$472,875.36||11,341|| |
|10/21/2016||Gene G Kinney||Insider||Sell||20,619||$55.10||$1,136,106.90||17,578|| |
|10/13/2016||Karin L Walker||Insider||Sell||5,000||$54.23||$271,150.00||3,000|| |
|9/19/2016||Karin L Walker||Insider||Sell||12,000||$61.10||$733,200.00||7,000|| |
|9/1/2016||Arthur W Homan||Insider||Sell||3,125||$52.16||$163,000.00||3,125|| |
|7/20/2016||Arthur W Homan||Insider||Sell||9,375||$52.14||$488,812.50||9,375|| |
|5/24/2016||Dennis J Selkoe||Director||Sell||5,000||$45.00||$225,000.00||3,025|| |
|4/13/2016||Karin L Walker||Insider||Sell||4,000||$45.11||$180,440.00||2,000|| |
|4/4/2016||Dennis J Selkoe||Director||Sell||5,000||$45.00||$225,000.00||7,845|| |
|1/13/2016||Karin L. Walker||insider||Sell||4,000||$50.96||$203,840.00|| |
|12/9/2015||Tara Nickerson||insider||Sell||10,000||$66.17||$661,700.00||2,000|| |
|12/9/2015||Tran Nguyen||CFO||Sell||30,000||$66.17||$1,985,100.00||2,200|| |
|12/1/2015||Dennis J. Selkoe||Director||Sell||3,125||$68.74||$214,812.50||2,845|| |
|11/27/2015||Christopher S. Henney||Director||Sell||5,000||$75.00||$375,000.00|| |
|11/25/2015||Lars Ekman||Director||Sell||30,000||$73.35||$2,200,500.00||243|| |
|11/13/2015||Martin Koller||insider||Sell||30,000||$65.03||$1,950,900.00|| |
|11/2/2015||Arthur W. Homan||insider||Sell||3,125||$52.14||$162,937.50|| |
|10/29/2015||Christopher S. Henney||Director||Sell||5,000||$55.00||$275,000.00|| |
|9/9/2015||Tara Nickerson||insider||Sell||10,000||$56.06||$560,600.00||2,000|| |
|9/2/2015||Martin Koller||insider||Sell||30,000||$55.56||$1,666,800.00|| |
|9/1/2015||Dennis J. Selkoe||Director||Sell||3,125||$55.45||$173,281.25||2,845|| |
|8/20/2015||Dale B. Schenk||CEO||Sell||30,000||$56.65||$1,699,500.00||3,333|| |
|8/12/2015||Karin L Walker||Insider||Sell||7,000||$62.06||$434,420.00|| |
|6/9/2015||Tara Nickerson||Insider||Sell||12,000||$44.41||$532,920.00|| |
|3/20/2015||Tara Nickerson||Insider||Sell||13,000||$39.99||$519,870.00|| |
|3/9/2015||Dennis J Selkoe||Director||Sell||3,125||$25.56||$79,875.00|| |
|8/12/2014||Karin L Walker||Insider||Sell||2,500||$20.74||$51,850.00|| |
|8/7/2014||Arthur W Homan||Insider||Buy||2,000||$19.12||$38,240.00|| |
|6/6/2014||Karin L Walker||Insider||Sell||8,000||$21.58||$172,640.00|| |
|5/12/2014||Dale Schenk||CEO||Buy||8,000||$20.79||$166,320.00||8,161|| |
|5/12/2014||Tara Nickerson||Insider||Buy||1,656||$21.00||$34,776.00||2,000|| |
|5/9/2014||Gene Kinney||Insider||Buy||2,500||$19.54||$48,850.00||2,793|| |
|5/9/2014||Tran Nguyen||CFO||Buy||2,200||$19.61||$43,142.00||2,200|| |
|2/3/2014||Co Plc Perrigo||major shareholder||Sell||3,182,253||$24.96||$79,429,034.88|| |
Prothena (NASDAQ PRTA) News Headlines
Prothena (NASDAQ:PRTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Prothena (NASDAQ:PRTA) Income Statement, Balance Sheet and Cash Flow Statement
Prothena (NASDAQ PRTA) Stock Chart for Thursday, March, 22, 2018